 |

 |
 |
 |

 |
Allergies

How you get them and how to get rid of them
6/06/1992 |
 |
|
 |
Cancer 
A new drug brings hope for managing the disease
5/28/2001 |
|
|
Indicates premium content.
|
|
 |
 |
 |
 |
 |
 E-mail your letter to the editor
|
 |
 |
|
 |
 |
So much is happening all at once during a migraine that it has been
hard to pinpoint what sets off the trigeminal nerve. Some scientists are
focusing on a wave of electrical activity that spreads across the brain
just before a migraine and triggers the aurathe shimmering light show
experienced by 1 in 5 migraine patients. Others wonder wheth-er there
is some kind of migraine generator buried deep within the brain stem.
Even when researchers think they know the order in which different parts
of the brain turn on during an attack, they can't always be sure if one
section is initiating an action or anticipating the need to respond.
What seems clear, however, is that the brain of a migraineur (as
sufferers are called) is primed to overreact to all sorts of stimuli that
most people can easily tolerate. "The brain receives input from a wide
variety of triggersstress, hormones, falling barometric pressure, food,
drink, sleep disturbances," says Dr. David Buchholz, a neurologist at
the Johns Hopkins University School of Medicine in Baltimore, Md. "Each
of us has his own stack of triggers and his own personal threshold at
which the migraine mechanism activates. The higher the trigger level
climbs above the threshold, the more fully activated the migraine
systemand the more pain."
In this view, people who are prone to migraine have a low threshold for
activating the trigeminal nerve. Those who suffer only an occasional
tension-type headache have a much higher threshold. Persistent treatment
of acute attacks and prevention of additional ones may reset the
brain's threshold point at a higher level.
Researchers are exploring the possibility that migraine sufferers are
not just hypersensitive to various triggers but that their brains have
lost some of their natural ability to suppress pain signals. To find out
more, scientists are studying a part of the brain called the
periaqueductal gray matter, which, says Dr. Welch in Kansas City, "switches off
the pain response so that you can focus on the fight to survive. It's
the reason why if you have a cut that you don't remember getting, it
doesn't start to hurt until you actually look at it."
Each time a migraine occurs, Welch and others have found, the
periaqueductal gray matter fills with oxygen, which triggers chemical reactions
that deposit iron in that section of the brain. As the iron builds up,
the brain's ability to block out pain decreases. That may explain why
many migraineurs become more sensitive to pain with each episode.
If overly sensitive nerve cells are the problem, it makes sense to try
to calm them down and that's exactly what the first drug tailored to
block an oncoming migraine was designed to do. Approved in the U.S. in
1993, sumatriptan mimics the action of a neurotransmitter called
serotonin, which plays many roles in the brain, including regulation of mood
and pain. In the case of migraines, the drug prevents nerve endings in
the dura from releasing their stimulatory proteins. No proteins, no
pain.
Sumatriptan's success launched a new class of drugs called triptans
that provide most migraineurs substantial relief. Like the painkillers
before them, the triptans deliver their best results when taken early in
an attack. Unfortunately, their effect is often temporary (drug
companies are working on longer-lasting versions). Also, the drugs can trigger
certain cardiovascular side effects, which means they should not be
used by patients who have an increased risk of heart attack or stroke.
Still, triptans have dramatically changed the lives of millions of
migraine sufferers and opened up promising areas of research. Scientists
have discovered that triptans, besides affecting serotonin pathways, also
directly block one of the stimulatory proteins released by the nerve
endings in the dura. New compounds that target this protein, dubbed cgrp,
are being tested in Europe. One big problem, says Lars Edvinsson of
Lund University in Sweden, "is that the drug can be given only
intravenously. We need a cgrp blocker that works as a tablet."
Pain relief isn't the only reason to stop a migraine before it goes too
far. When the illness goes untreated, there is some evidence "of a
mechanism in the central nervous system that makes traditional medications
less useful," says Dr. Michael Moskowitz, a neurologist at Harvard
Medical School in Boston. How that resistance develops is the subject of
intense investigation.
 |
 |
 |

BUSINESS
Can McDonald's Shape Up?
Will a broader menu and spiffy new digs get the burger giant on track?
ASIA
Accounted for, at Last
North Korea admits it abducted Japanese citizens to help train its spies and says some are still alive
|
 |
SCIENCE
Not in My Back Bay
Everybody likes the idea of windmills, but nobody wants to live near them not even in Massachusetts
ARTS
Beck Gets (Kind of) Blue
With a revealing new album of mournful ballads, the fusion king reveals a whole different side
|
|
 |
 |
|
 |
 |


|
 |